Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05439772 · ClinicalTrials.gov registry record · Phase 4
Examining the Effect of Ondansetron on Bowel Prep Success
A Phase 4 study of Weight Loss and Inflammatory Bowel Diseases, sponsored by State University of New York - Downstate Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT05439772: Completed Phase 4 study of Weight Loss and Inflammatory Bowel Diseases, sponsored by State University of New York - Downstate Medical Center.
NCT05439772 is a Phase 4 study of Weight Loss and Inflammatory Bowel Diseases that has completed, run by State University of New York - Downstate Medical Center. The registered enrollment target is 41 participants, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05439772, a Phase 4 study of Weight Loss and Inflammatory Bowel Diseases, has completed, sponsored by State University of New York - Downstate Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot randomized-controlled trial assessing the utility of ondansetron for improving pediatric pre-colonoscopy bowel prep outcomes using the boston bowel preparation score, as well as assessing the impact on patient experience of bowel preparation.
Primary Outcome
validated scoring system of bowel preparation
Conditions Studied
Interventions
- DRUG Ondansetron
Study Locations (1)
New York
- SUNY Downstate University Hospital of Brooklyn - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2023-07-01 |
| Phase | Phase 4 |
What the finished NCT05439772 record still lists
NCT05439772 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (97% lower).
The record links to 6 conditions, with Weight Loss appearing as the primary indexed condition, and to 1 intervention - of which Ondansetron is the first listed.
NCT05439772 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05439772 about?
NCT05439772 is a clinical study titled "Examining the Effect of Ondansetron on Bowel Prep Success". This is a pilot randomized-controlled trial assessing the utility of ondansetron for improving pediatric pre-colonoscopy bowel prep outcomes using the boston bowel preparation score, as well as assessing the impact on patient experience of bowel preparation.
What is the current status of trial NCT05439772?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2021-01-01. Estimated completion is 2023-07-01.
What conditions does trial NCT05439772 study?
This clinical trial studies the following conditions: Weight Loss, Inflammatory Bowel Diseases, Diarrhea, Abdominal Pain, Eosinophilic Gastroenteritis.
What interventions are being tested in trial NCT05439772?
The interventions under investigation include: Ondansetron (DRUG).
Who is sponsoring clinical trial NCT05439772?
This trial is sponsored by State University of New York - Downstate Medical Center, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05439772 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05439772's enrollment target sits among peer trials
41 86th of 116 higher than 31 of 116 other Weight Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
-
Lorcaserin in Obesity: Identification of CNS Targets Using FMRI
ACTIVE NOT RECRUITING · Phase 4
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
RECRUITING
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI